Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pee break: spot urine test could end 24-Hour jug hassle for myeloma patients

NCT ID NCT05208086

Diagnosis Sponsor: Intergroupe Francophone du Myelome Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single urine sample (spot urine) can detect myeloma proteins as accurately as the standard 24-hour urine collection. Researchers will compare results from 180 multiple myeloma patients starting a new treatment. If the spot test works well, it could make monitoring much easier for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could replace the inconvenient 24-hour urine collection with a simple spot urine test for monitoring multiple myeloma.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial. The spot test may not be sensitive enough to replace the standard method, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2022

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with Multiple Myeloma whatever the line of treatment started in one of the twenty investigators sites located in France.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with Multiple Myeloma * Patient starting new treatment line, whatever the line is, but with at least 3 induction cycles * Urine monoclonal component ≥ 200mg/24h Exclusion Criteria: Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • CH Bretagne Atlantique Vannes et Auray-P.Chubert

    Vannes, France

  • CH de Dunkerque

    Dunkirk, France

  • CH de Lens

    Lens, France

  • CH de Versailles

    Versailles, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHRU Bretonneau

    Tours, France

  • CHRU Nantes

    Nantes, France

  • CHU François Mitterand

    Dijon, France

  • CHU Toulouse

    Toulouse, France

  • CHU de Montpellier

    Montpellier, France

  • Centre Hospitalier Lyon sud

    Lyon, France

  • Centre Hospitalier Métropole de Savoie

    Chambéry, France

  • Ch Annecy Genevois

    Annecy, France

  • Ch Le Mans

    Le Mans, France

  • Chu Pontchaillou

    Rennes, France

  • Hopital Bicètre

    Le Kremlin Bicètre, France

  • Hopital Claude Huriez-CHRU LILLE

    Lille, France

  • Hôpital E. MULLER

    Mulhouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.